R. Kulkarni

发表

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients

M. Boffito, I. Patel, P. N. Morcos, 2015, Drugs in R&D.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.

Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate COVID-19 virus pneumonia: results of stage 1 of the study.

Mazhar I. Khan, A. Sharma, P. Badhe, 2022, American journal of stem cells.

Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study

Patrick F. Smith, Ya-Chi Chen, J. Haznedar, 2014, Clinical pharmacology in drug development.

Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on QTc Interval in Healthy Subjects: Results from a Thorough QT Study

P. N. Morcos, Patrick F. Smith, B. Brennan, 2013 .

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

R. Petric, E. Gane, D. Larrey, 2013, Antimicrobial Agents and Chemotherapy.

The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine

William Smith, T. Marbury, R. Robson, 2014, Drug development research (Print).

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

S. Pol, G. Foster, E. Yoshida, 2015, Journal of hepatology.

JUMP‐C: A randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients

C. Cooper, P. Pockros, D. Jensen, 2013, Hepatology.

Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.

C. Bernaards, Patrick F. Smith, Ya-Chi Chen, 2014, British journal of clinical pharmacology.

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

Stuart K. Roberts, R. Elston, P. Angus, 2012, Gastroenterology.

Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)

Shashank Srivastava, A. Maurya, N. Sachdeva, 2020, medRxiv.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.